Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise (NASDAQ:ALKS)

seekingalpha.com · 2026-09-11

Alkermes plc upgraded to Buy on strong revenue growth, Lumryz momentum, and orexin pipeline upside in sleep/CNS—click to get the latest ALKS outlook now.

Read the full story at seekingalpha.com →